Key facts
- It has raised $159.7M; the latest was Later Stage VC ($101.9M) in Jun 2024.
- Notable investors include Ecole Polytechnique Federale de Lausanne, M Ventures, Schroders Capital, Vi Partners, 3B Future Health Fund — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for iOnctura
- ·The full record, as it builds
Funding rounds
No funding rounds for iOnctura are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iOnctura
Developer of next-generation bio-molecules intended for the treatment of cancer and fibrosis. The company's bio-molecules include novel therapeutics that modulate key components of immunosuppression in the tumor microenvironment, enabling doctors to identify and treat cancer effectively.
- Sector
- Healthcare
- HQ
- Genève, Switzerland
- Founded
- 2017
- Employees
- 33
- Website
- ionctura.com/
- Ownership
- Privately Held (backing)
iOnctura doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iOnctura shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iOnctura in its N-PORT filings yet. We sweep new filings monthly.